The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 Update

Alexander L. Miller, Catherine S. Hall, Robert W. Buchanan, Peter F Buckley, John A. Chiles, Robert R. Conley, M. Lynn Crismon, Larry Ereshefsky, Susan M. Essock, Molly Finnerty, Stephen R. Marder, Del D. Miller, Joseph Patrick McEvoy, A. John Rush, Sy A. Saeed, Nina R. Schooler, Steven P. Shon, Scott Stroup, Bernardo Tarin-Godoy

Research output: Contribution to journalReview article

164 Citations (Scopus)

Abstract

Background: The Texas Medication Algorithm Project (TMAP) has been a public-academic collaboration in which guidelines for medication treatment of schizophrenia, bipolar disorder, and major depressive disorder were used in selected public outpatient clinics in Texas. Subsequently, these algorithms were implemented throughout Texas and are being used in other states. Guidelines require updating when significant new evidence emerges; the antipsychotic algorithm for schizophrenia was last updated in 1999. This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators. Method: A conference in January 2002 began the update process. Before the conference, experts in the pharmacologic treatment of schizophrenia, clinicians, and administrators reviewed literature topics and prepared presentations. Topics included ziprasidone's inclusion in the algorithm, the number of antipsychotics tried before clozapine, and the role of first generation antipsychotics. Data were rated according to Agency for Healthcare Research and Quality criteria. After discussing the presentations, conference attendees arrived at consensus recommendations. Consideration of aripiprazole's inclusion was subsequently handled by electronic communications. Results: The antipsychotic algorithm for schizophrenia was updated to include ziprasidone and aripiprazole among the first-line agents. Relative to the prior algorithm, the number of stages before clozapine was reduced. First generation antipsychotics were included but not as first-line choices. For patients refusing or not responding to clozapine and clozapine augmentation, preference was given to trying monotherapy with another antipsychotic before resorting to antipsychotic combinations. Conclusion: Consensus on algorithm revisions was achieved, but only further well-controlled research will answer many key questions about sequence and type of medication treatments of schizophrenia.

Original languageEnglish (US)
Pages (from-to)500-508
Number of pages9
JournalJournal of Clinical Psychiatry
Volume65
Issue number4
DOIs
StatePublished - Apr 1 2004

Fingerprint

Antipsychotic Agents
Schizophrenia
Clozapine
Administrative Personnel
Consensus
Guidelines
Health Services Research
Major Depressive Disorder
Ambulatory Care Facilities
Bipolar Disorder
Therapeutics
Communication
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Miller, A. L., Hall, C. S., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., ... Tarin-Godoy, B. (2004). The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 Update. Journal of Clinical Psychiatry, 65(4), 500-508. https://doi.org/10.4088/JCP.v65n0408

The Texas medication algorithm project antipsychotic algorithm for schizophrenia : 2003 Update. / Miller, Alexander L.; Hall, Catherine S.; Buchanan, Robert W.; Buckley, Peter F; Chiles, John A.; Conley, Robert R.; Crismon, M. Lynn; Ereshefsky, Larry; Essock, Susan M.; Finnerty, Molly; Marder, Stephen R.; Miller, Del D.; McEvoy, Joseph Patrick; Rush, A. John; Saeed, Sy A.; Schooler, Nina R.; Shon, Steven P.; Stroup, Scott; Tarin-Godoy, Bernardo.

In: Journal of Clinical Psychiatry, Vol. 65, No. 4, 01.04.2004, p. 500-508.

Research output: Contribution to journalReview article

Miller, AL, Hall, CS, Buchanan, RW, Buckley, PF, Chiles, JA, Conley, RR, Crismon, ML, Ereshefsky, L, Essock, SM, Finnerty, M, Marder, SR, Miller, DD, McEvoy, JP, Rush, AJ, Saeed, SA, Schooler, NR, Shon, SP, Stroup, S & Tarin-Godoy, B 2004, 'The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 Update', Journal of Clinical Psychiatry, vol. 65, no. 4, pp. 500-508. https://doi.org/10.4088/JCP.v65n0408
Miller, Alexander L. ; Hall, Catherine S. ; Buchanan, Robert W. ; Buckley, Peter F ; Chiles, John A. ; Conley, Robert R. ; Crismon, M. Lynn ; Ereshefsky, Larry ; Essock, Susan M. ; Finnerty, Molly ; Marder, Stephen R. ; Miller, Del D. ; McEvoy, Joseph Patrick ; Rush, A. John ; Saeed, Sy A. ; Schooler, Nina R. ; Shon, Steven P. ; Stroup, Scott ; Tarin-Godoy, Bernardo. / The Texas medication algorithm project antipsychotic algorithm for schizophrenia : 2003 Update. In: Journal of Clinical Psychiatry. 2004 ; Vol. 65, No. 4. pp. 500-508.
@article{2aec47170b004aa2955f0fac2309ce1a,
title = "The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 Update",
abstract = "Background: The Texas Medication Algorithm Project (TMAP) has been a public-academic collaboration in which guidelines for medication treatment of schizophrenia, bipolar disorder, and major depressive disorder were used in selected public outpatient clinics in Texas. Subsequently, these algorithms were implemented throughout Texas and are being used in other states. Guidelines require updating when significant new evidence emerges; the antipsychotic algorithm for schizophrenia was last updated in 1999. This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators. Method: A conference in January 2002 began the update process. Before the conference, experts in the pharmacologic treatment of schizophrenia, clinicians, and administrators reviewed literature topics and prepared presentations. Topics included ziprasidone's inclusion in the algorithm, the number of antipsychotics tried before clozapine, and the role of first generation antipsychotics. Data were rated according to Agency for Healthcare Research and Quality criteria. After discussing the presentations, conference attendees arrived at consensus recommendations. Consideration of aripiprazole's inclusion was subsequently handled by electronic communications. Results: The antipsychotic algorithm for schizophrenia was updated to include ziprasidone and aripiprazole among the first-line agents. Relative to the prior algorithm, the number of stages before clozapine was reduced. First generation antipsychotics were included but not as first-line choices. For patients refusing or not responding to clozapine and clozapine augmentation, preference was given to trying monotherapy with another antipsychotic before resorting to antipsychotic combinations. Conclusion: Consensus on algorithm revisions was achieved, but only further well-controlled research will answer many key questions about sequence and type of medication treatments of schizophrenia.",
author = "Miller, {Alexander L.} and Hall, {Catherine S.} and Buchanan, {Robert W.} and Buckley, {Peter F} and Chiles, {John A.} and Conley, {Robert R.} and Crismon, {M. Lynn} and Larry Ereshefsky and Essock, {Susan M.} and Molly Finnerty and Marder, {Stephen R.} and Miller, {Del D.} and McEvoy, {Joseph Patrick} and Rush, {A. John} and Saeed, {Sy A.} and Schooler, {Nina R.} and Shon, {Steven P.} and Scott Stroup and Bernardo Tarin-Godoy",
year = "2004",
month = "4",
day = "1",
doi = "10.4088/JCP.v65n0408",
language = "English (US)",
volume = "65",
pages = "500--508",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - The Texas medication algorithm project antipsychotic algorithm for schizophrenia

T2 - 2003 Update

AU - Miller, Alexander L.

AU - Hall, Catherine S.

AU - Buchanan, Robert W.

AU - Buckley, Peter F

AU - Chiles, John A.

AU - Conley, Robert R.

AU - Crismon, M. Lynn

AU - Ereshefsky, Larry

AU - Essock, Susan M.

AU - Finnerty, Molly

AU - Marder, Stephen R.

AU - Miller, Del D.

AU - McEvoy, Joseph Patrick

AU - Rush, A. John

AU - Saeed, Sy A.

AU - Schooler, Nina R.

AU - Shon, Steven P.

AU - Stroup, Scott

AU - Tarin-Godoy, Bernardo

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Background: The Texas Medication Algorithm Project (TMAP) has been a public-academic collaboration in which guidelines for medication treatment of schizophrenia, bipolar disorder, and major depressive disorder were used in selected public outpatient clinics in Texas. Subsequently, these algorithms were implemented throughout Texas and are being used in other states. Guidelines require updating when significant new evidence emerges; the antipsychotic algorithm for schizophrenia was last updated in 1999. This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators. Method: A conference in January 2002 began the update process. Before the conference, experts in the pharmacologic treatment of schizophrenia, clinicians, and administrators reviewed literature topics and prepared presentations. Topics included ziprasidone's inclusion in the algorithm, the number of antipsychotics tried before clozapine, and the role of first generation antipsychotics. Data were rated according to Agency for Healthcare Research and Quality criteria. After discussing the presentations, conference attendees arrived at consensus recommendations. Consideration of aripiprazole's inclusion was subsequently handled by electronic communications. Results: The antipsychotic algorithm for schizophrenia was updated to include ziprasidone and aripiprazole among the first-line agents. Relative to the prior algorithm, the number of stages before clozapine was reduced. First generation antipsychotics were included but not as first-line choices. For patients refusing or not responding to clozapine and clozapine augmentation, preference was given to trying monotherapy with another antipsychotic before resorting to antipsychotic combinations. Conclusion: Consensus on algorithm revisions was achieved, but only further well-controlled research will answer many key questions about sequence and type of medication treatments of schizophrenia.

AB - Background: The Texas Medication Algorithm Project (TMAP) has been a public-academic collaboration in which guidelines for medication treatment of schizophrenia, bipolar disorder, and major depressive disorder were used in selected public outpatient clinics in Texas. Subsequently, these algorithms were implemented throughout Texas and are being used in other states. Guidelines require updating when significant new evidence emerges; the antipsychotic algorithm for schizophrenia was last updated in 1999. This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators. Method: A conference in January 2002 began the update process. Before the conference, experts in the pharmacologic treatment of schizophrenia, clinicians, and administrators reviewed literature topics and prepared presentations. Topics included ziprasidone's inclusion in the algorithm, the number of antipsychotics tried before clozapine, and the role of first generation antipsychotics. Data were rated according to Agency for Healthcare Research and Quality criteria. After discussing the presentations, conference attendees arrived at consensus recommendations. Consideration of aripiprazole's inclusion was subsequently handled by electronic communications. Results: The antipsychotic algorithm for schizophrenia was updated to include ziprasidone and aripiprazole among the first-line agents. Relative to the prior algorithm, the number of stages before clozapine was reduced. First generation antipsychotics were included but not as first-line choices. For patients refusing or not responding to clozapine and clozapine augmentation, preference was given to trying monotherapy with another antipsychotic before resorting to antipsychotic combinations. Conclusion: Consensus on algorithm revisions was achieved, but only further well-controlled research will answer many key questions about sequence and type of medication treatments of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=2442473932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442473932&partnerID=8YFLogxK

U2 - 10.4088/JCP.v65n0408

DO - 10.4088/JCP.v65n0408

M3 - Review article

C2 - 15119912

AN - SCOPUS:2442473932

VL - 65

SP - 500

EP - 508

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 4

ER -